natgillin/translations-raw huggingface dataset:
Earlier sunscreening formulations were designed to protect against sunburn from a limited solar exposure period, while transmitting sufficient radiation to permit skin tanning. 
Prijašnji pripravci za zaštitu od sunca su bili zamišljeni da štite od sunčanih opeklina u ograničenom periodu izlaganja suncu, dok propuštaju dovoljno zračenja da omoguće tamnjenje kože.
The lead composition of clause 23 wherein the mixed matrix has a density of less than 1 g/cm3. 
Supstancu olova sukladno patentnom zahtjevu 12 pri čemu je miješana matrica gustoće manje od 3 g/em', ili pri čemu je miješana matrica gustoće manje od 1 g/cm'.
and pharmaceutically acceptable solvates thereof. A salt according to claim 4 selected from the group consisting of: 
Sol iz zahtjeva 4 naznačena time da odabrana iz skupine koju čine:
In another aspect of the invention, a method is provided comprising mixing the solution of the preparing step and sample for at least 5 seconds and incubating at about 21°C for at least about 1 minute. 
Postupak prema bilo kojem prethodnom zahtjevu, naznačen time što otopina iz koraka priprave i uzorak se miješaju najmanje 5 sekundi i inkubiraju pri 21 *€ najmanje 1 minutu.
PCT/EP03/12338 filed by this same Applicant) is illustrated in FIG. 7, where it is generally indicated with the reference numeral 200 . 
PCT/EP03/12338, podnesenu od strane istog Podnositelja) prikazana je na Slici 7, gdje je to općenito označeno referentnim brojem 200.
drying of the surface of the washed strip; 
sušenje površine oprane trake;
Isotopically labeled compounds of the present invention can generally be prepared by following procedures analogous to those disclosed in the Schemes supra and Examples infra, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent. 
Izotopno označeni spojevi prikazanog izuma mogu općenito biti pripremljeni HR P20060286 T3 slijedećim postupcima analogno onima opisanim u Schemes supra and Examples infra, supstitucijom izotopno označenog reagensa sa ne-izotopno označenim reagensom.
Crystallizing the complex formed in step b) 
izborno, izoliranje kompleksa dobivenog u koraku b).
The method as in embodiment 5, wherein the method further comprises the step of applying moisture on the resin (5) in powder form. 
Metoda u skladu sa bilo kojim od prethodnih patentnih zahtjeva, gdje metoda dalje sadrži korak nanošenja vlage na smolu u obliku praha.
3 that shows, in a diagrammatic way and in correspondence with a progressive thickness reduction, also the increasing power consumption in the first five rolling stands, as indicated by the corresponding size of the each one of the stands. 
Gore navedeno se može vidjeti na Slici 3 koja prikazuje, na grafički način i u odnosu na progresivno smanjenje debljine, također povećanu potrošnju snage na prvih pet valjačkih stanova, kako je naznačeno odgovarajućom veličinom svakog od stanova.
The kit according to claim 1, wherein the inside of the first and second syringe containers (20) and (21), needle containers (24) and connector containers (23) is in the aseptic and sterile state. 
Komplet u skladu s patentnim zahtjevom 1, naznačen time što su unutrašnjosti spremnika za prve i druge štrcaljke (20) i (21), spremnika za igle (24) i spremnika za konektore (23) u aseptičnom i sterilnom stanju.
The formulation of claim 1, wherein the formulation has less than 10% degradation when stored at 2-8°C for 2 years. 
Formulacija iz patentnog zahtjeva 1, pri čemu formulacija ima manje od 10% raspadanja kada se čuva na 2-8°C tijekom 2 godine.
wherein Z is CH2 and t is an integer equal to 2. 
(CHoeh pri čemu Z je CH, i tje cijeli broj jednak 2.
The method according to claim 1, wherein the pharmaceutical product is selected from the group consisting of: azacytidine, belinostat, bendamustine, brentuximab vedotin, bleomycin, bortezomib, busulfan, carboplatin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, decitabine, deferoxamine, doxorubicin, epirubicin hydrochloride, fludarabine, fotemustine, fulvestrant, gemcitabine, idarubicin, ifosfamide, irinotecan hydrochloride, ixabepilone, melphalan, methotrexate, oxaliplatin, paclitaxel, pemetrexed, pentostatin, raltitrexed, romidepsin, temozolomide, thiotepa, topotecan, trabectedin, trastuzumab, and vinblastine. 
Farmaceutska vrećica u skladu s patentnim zahtjevom 8, naznačena time, da je citotoksični lijek odabran iz skupine koju tvore: azacitidin, belinostat, bendamustin, brentuksimab vedotin, bleomicin, bortezomib, busulfan, karboplatin, ciklofosfamid, citarabin, dakarbazin, daktinomicin, daunorubicin, decitabin, deferoksamin, doksorubicin, epirubicin hidroklorid, fludarabin, fotemustin, fulvestrant, gemcitabin, idarubicin, ifosfamid, irinotekan hidroklorid, iksabepilon, melfalan, metotreksat, oksaliplatin, paklitaksel, pemetreksed, pentostatin, raltitreksed, romidepsin, temozolomid, tiotepa, topotekan, trabektedin, trastuzumab i vinblastin.
The apparatus of claim 1, wherein, when the one available intra prediction mode is a DC mode, the two additional intra prediction modes include a planar mode and the vertical mode. 
Metoda prema zahtjevu 1, naznačena time da je dostupni unutarokovirni načina predviđanja DC način, dva dodatna unutarokovirna načina predviđanja uključuje planarni 1 vertikalni način.
or an N -oxide or a salt thereof, for use in protecting an animal from a parasitic invertebrate pest, wherein the compound is administered orally, the animal to be protected is a cat or dog and the parasitic invertebrate pest is a flea, tick or mite. 
Uporaba prema zahtjevu 7, naznačena time, da se kod životinje koja se treba zaštititi, radi o mački ili psu, a parazitni štetočina beskičmenjak je buha, krpelj ili rastoč.
Pirfenidone for use according to claim 1, wherein, prior to step (a), pirfenidone is administered at doses lower than 1600 mg/day for a time period. 
Pirfenidon za upotrebu u liječenju pacijenta prema zahtjevu 2, gdje se prije stupnja (a) spomenutom pacijentu daje pirfenidon u dozama manjim od 2400 mg/dan u tijeku vremenskog perioda.
is alkyl optionally substituted by 1 or 2 substituents selected from the group consisting of a halogen atom and hydroxyl; alkoxy; haloalkoxy; a chlorine atom; cyano; cyclopropyl; nitro; amino; formyl; alkenyl or alkynyl; or 
R* je atom vodika; alkil prema potrebi supstituiran s jednim do dva supstituenta odabrana iz skupine koju čine atom halogena i hidroksil; alkoksi; haloalkoksi; atom halogena; cijano; ciklopropil; nitro; amino; formil; alkenil ili alkinil; ili
The structure of the floors 15 - 17 is similar, except for some differences in finishing. 
Građa katova 15-17 je jednaka, osim nekih razlika u završnoj obradi.
The pharmaceutical composition for use according to claim 11, wherein the disorder is cancer, such as lymphoma. 
Spoj za uporabu ili sastav za uporabu prema zahtjevu 8 ili 9, pri čemu poremećaj je multipla skleroza.
The multipurpose airway device as claimed in any one of the preceding claims, wherein the multipurpose airway device is of suitable size for an adult patient and the airway body has an elliptical cross-section; and optionally wherein the external conjugate diameter of the airway body is in the range of from approximately 15 mm to approximately 50 mm, e.g. 
Višenamjenski uređaj za disanje sukladno bilo kojem prethodnom zahtjevu, pri čemu je višenamjenski uređaj za disanje prikladan za odrasle, a cjevasto tijelo ima eliptični poprečni presjek; i eventualno pri čemu je vanjski konjugirani promjer cjevastog tijelo u rasponu između približno 15 150 mm, npr.
putting the container in place in the dialysis machine and introducing the connecting portion or portions into the corresponding ports of the machine; and 
postavljanje spremnika u aparat za dijalizu i uvođenje spojnog dijela ili dijelova (91, 92) u odgovarajuće priključke aparata i
Use of a compound according to claim 10, wherein the disorder or disease is characterized by an abnormal activity of aldosterone synthase. 
Uporaba spoja prema zahtjevu 10, naznačena time, da je poremećaj ili bolest karakteriziran(a) s nenormalnim djelovanjem sinteze aldosterona,
This capsule is completed by an upper wall formed by a membrane. 
Ovu kapsulu kompletira stropnica, koju čini membrana.
The method of claim 24, wherein the antibody or the antibody fragment is an anti-MET antibody or an anti-MET antibody fragment. The method of claim 31, wherein nucleic acid encoding an anti-MET antibody or an anti-MET antibody fragment is selected from the group consisting of nucleic acid encoding the amino acid sequence of SEQ ID NO:50, nucleic acid encoding the amino acid sequence of SEQ ID NO:51, and nucleic acid encoding the amino acid sequence of SEQ ID NO:52. 
Postupak prema patentnom zahtjevu 6, naznačen time, da protutijelo ili fragment protutijela je anti-MET protutijelo ili fragment anti-MET protutijela. Postupak prema patentnom zahtjevu 12, naznačen time, da je nukleinska Kiselina koja kodira anti-MET protutijelo ili fragment anti-MET protutijela odabrana iz skupine koju čine nukleinska kiselina koja kodira aminokiselinsku sekvencu ID BR: SEK.:50, nukleinska kiselina koja kodira aminokiselinsku sekvencu ID BR. SEK.:51 te nukleinska kiselina koja kodira aminokiselinsku sekvencu ID BR.
A fluid distribution system according to claim 13, said fluid distribution system being arranged to supply fluid to a load, said fluid distribution system comprising: said load, 
Sustav (1000a) za distribuciju fluida prema zahtjevu 13, pri čemu je navedeni Sustav (10004) za distribuciju fluida prilagođen za napajanje opterećenja fluidom, navedeni Sustav za distribuciju fluida sadrži:
Fixed combination, non-fixed combination or kit of parts comprising the compound according to claim 9, at least one therapeutic agent selected from the group consisting of corticosteroids, anticholinergics, B2-adrenoceptor agonists, H1 receptor antagonists, leukotriene receptor antagonists, type 5 phosphodiesterase inhibitors, HMG-CoA reductase inhibitors, lung surfactants, antibiotics and anti-diabetic agents, and at least one pharmaceutically acceptable auxiliary. 
Fiksirana kombinacija, nefiksirana kombinacija ili garnitura od segmenata, naznačena time, da obuhvaća spoj prema zahtjevu 9, barem jedno terapeutsko sredstvo odabrano iz skupine koju čine kortikosteroidi, antikolinergici, agonisti B2-adrenoceptora, antagonisti H1 receptora, antagonisti leukotrien receptora, inhibitori fosfodiesteraze tipa 5, inhibitori HMG-CoA reduktaze, plućni surfaktanti, antibiotici i antidijabetička sredstva, te barem jedno farmaceutski prihvatljivo pomoćno sredstvo.
Use according to any one of claims 1 to 6, wherein said ionizing radiations are selected in the group consisting of X-Rays, Y-Rays, electron beams and radioisotope emissions. 
Uporaba prema bilo kojem od zahtjeva 1 i 4, ili nanočestice HfO2 ili agregati nanočestica HfO2 za uporabu prema bilo kojem od zahtjeva 2, 3 i 4, gdje su spomenuta ionizirajuća zračenja odabrana iz skupine koju čine X-zrake, Y-zrake, elektronski snopovi i zračenja radioizotopa.
wherein np is the number of packets in the frame, nap is the number of affected transport streams (TS) packets in the hit frame, nlp is the number of lost packets in the frame, nle is the number of loss events in the frame, and nsl is the number of slices in the frame. 
2x nsl gdje je np broj paketa u kadru, nap je broj oštećenih paketa transportnih struja (TS) u oštećenom kadru, nip je broj izgubljenih paketa u kadru, nle je broj pojava gubitka u kadru, a nsl je broj odsječaka u kadru.
The formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy. 
Formulacije se mogu prikladno prezentirati 1 u obliku doznih jedinica metodama poznatim u farmaceutskoj struci.
The method of claim 1, wherein the cation exchange resin is regenerated in acid form, and/or wherein the anion exchange resin is regenerated in alkali form. 
Postupak prema patentnom zahtjevu 1, naznačen time što se smola za izmjenu kationa regenerira u kiseloj formi, 1 /ili gdje se smola za izmjenu aniona regenerira u alkalnom obliku.
For administration by inhalation, the powdered formulations typically comprise the active compound together with an inert solid powdered diluent such as lactose. 
Za primjenu inhaliranjem, praškaste formulacije obično sadrže aktivni spoj skupa s inerntnim krutim praškastim sredstvom za razrijeđivanje poput laktoze.
A composition according to any one of claims 3 to 7, for use in treating or preventing a disease in the upper respiratory tract caused by pathogenic organisms such as viruses, bacteria and fungus. 
liječenju ili prevenciji bolesti u gornjem respiratornom traktu uzrokovane patogenim organizmima kao što su virusi, bakterije i gljivice;
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use in a method according to any of embodiments 1-13, wherein the method comprises initiating administration of a therapeutically effective amount of acetyl-leucine to the subject in need thereof when the subject is asymptomatic. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema bilo kojem od zahtjeva 1-8, pri čemu uporaba sadrži iniciranje primjene terapeutski djelotvorne količine acetil-leucina na subjektu kojemu je to potrebno kada je subjekt bez simptoma.
The CD19xCD3 bispecific single chain antibody construct for the use of any of claims 1 to 14, wherein the CD19xCD3 bispecific single chain antibody construct is to be administered in a daily dose of 10µg to 100µg per square meter patient body surface area. 
CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time što CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt treba primijeniti u dnevnoj dozi od 10 µg do 100 µg po kvadratnom metru površine pacijentovog tijela.
The method of any one of claims 1 to 7, 14 and 15, wherein the rf allele is linked to and/or associated with the SSR markers consisting of a PCR fragment with an apparent molecular weight of 240.8 (+/- 0.4) bp resulting from a PCR reaction with the primers having the sequences set forth as SEQ ID NOs: 19 and 20. 
Postupak prema bilo kojem od zahtjeva 1 do 7, 14 i 15 naznačen time da rf alel is vezan sa i/ili udružen sa SSR markerima koji se sastoje od PCR fragmenta sa očitom molekularnom težinom od 240,8 (+/- 0.4) bp koja proizlazi iz PCR reakcije sa početnicama koje imaju sekvence navedene kao SEQ ID NOs: 191 20.
R1a is optionally substituted aryl or heteroaryl; 
Q je po izboru supstituirani aril ili heteroaril; i
Item-11) Device according to item 10, wherein the intermediate chamber is tapers toward the dosing recess. 
Točka-11) Uređaj prema točki 10, pri čemu se međukomora sužava prema utoru za doziranje.
The device according to one of Claims 7 or 11 to 12, characterized in that the pressure source (146) comprises a piston (124) or a membrane which can be electromagnetically displaced and/or deformed in order to vary the pressure in the fluid volume (126). 
Uređaj u skladu s jednim od patentnih zahtjeva 6 ili 10 do 11, naznačen time, da se izvor tlaka (146) sastoji od klipa (124) ili membrane koja se može elektromagnetski pomaknuti i / ili deformirati kako bi se mijenjao tlak u prostoru za fluid (126).
According to this sixth variant, the said additive preferentially contains 25% to 95%, more preferentially 45% to 90%, and very preferentially 75% to 85%, by weight of polyglycerols relative to their total weight, the remainder consisting of water. 
Postupak prema zahtjevu 19, naznačen time da navedeni aditiv sadrži 25% do 95%, po mogućnosti 45% do 90%, te vrlo poželjno 75% do 85%, težinski poliglicerola u odnosu na njihovu ukupnu težinu, dok se ostatak sastoji od vode.
a decrease from baseline in SCORing Atopic Dermatitis (SCORAD) score of at least 30%; 
(IV) smanjenje rezultata prema Ljestvici za procjenu atopijskog dermatitisa (SCORAD) za najmanje 30 % u odnosu na osnovicu;
Formulation according to claim 6, wherein the buffer solution is an aqueous citrate buffer. 
Formulacija u skladu s patentnim zahtjevom 6, naznačena time što puferska otopina je vodeni citratni pufer.
The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein the compound has a formula of Formula IX The compound of claims 2 or 3, or a pharmaceutically acceptable salt thereof, wherein the compound has a formula of Formula VII-1 
Tvar iz patentnog zahtjeva 2, ili njena farmaceutski prihvatljiva sol, pri čemu tvar ima formulu prikazanu Formulom IX Tvar iz patentnih zahtjeva 2 ili 3, ili njena farmaceutski prihvatljiva sol, pri čemu tvar ima formulu prikazanu
The polyalkylene oxide-adenosine deaminase conjugate of claim 7, wherein the polyethylene glycol is conjugated to the recombinant adenosine deaminase via a linker selected from the group consisting of succinimidyl carbonate, thiazolidine thione, urethane, and amide based linkers. 
Konjugat adenozin deaminaze i polialkilen oksida u skladu s patentnim zahtjevom 7, naznačen time, da je polietilen glikol konjugiran do rekombinantne adenozin deaminaze preko linkera odabranog iz skupine koju čine sukcinimidil karbonata, tiazolidin tion, uretan i linkeri na bazi amida.
is hydrogen or lower alkyl; or a pharmaceutically acceptable acid addition salt, a racemic mixture, or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. 
R> je vodik ili C,-alkil; ili njegova farmaceutski prihvatljiva kiselinska adicijska sol, racemična smjesa, ili njegov odgovarajući enantiomer i/ili optički izomer i/ili stereoizomer.
Cortexolone-17a-propionate in crystalline form III according to claim 15, characterised by a DRX spectrum as represented in Figure 7 and a DSC spectrum as represented in Figure 8, and by an IR spectrum as represented in Figure 9. 
Korteksolon-17a-propionat u kristalnom obliku II u skladu s patentnim zahtjevom 15, naznačen time što ima DRX spektar, kao što je prikazan na Slici 7 1 DSC spektar, kao što je prikazan na Slici 8, te što ima IR spektar, kao što je prikazan na Slici 9.
mg of said oxycodone or pharmaceutically acceptable salt thereof, and at least 72% by weight of said high molecular weight polyethylene oxide; 
mg oksikodon hidroklorida; i pri čemu pripravak sadrži barem oko 65 % (težinski) polietilen oksida.
a non-ionic hydrophilic surfactant having a high hydrophilic-lipophilic balance (HLB) value between 13 and 40; and 
(vi) neionski hidrofilni tenzid koji ima visoku vrijednost hidrofilno-lipofilne ravnoteže (visoku HLB- vrijednost) - između 13140; 1
Once a saturated solution is achieved (approximately 10 g per 100 ml), the solution is treated with copper (II) chloride (4 g) in water (5 ml). 
Kad se dobije zasićenu otopinu (približno 10 g na 100 ml), otopinu se pomiješa s bakrenim (Il) kloridom (4 g) u vodi (5 ml).
a solution, comprising at least one lignin and also at least one fibre-forming polymer selected from the group consisting of polyacrylonitrile and polyacrylonitrile-copolymers in at least one solvent, 
otopina, koja se sastoji od barem jedne vrste lignina i barem jednog polimera koji tvori vlakna odabranog iz skupine koja se sastoji od celuloze ili derivata celuloze u barem jednoj otopini, odabranoj iz skupine tercijarnih amin oksida i/ili ionskih tekućina,
is as in formula I, and E is an amino protecting group PG1 or a group of formula -A4-G, wherein 
R5 je kao u formuli [; i E je zaštitna skupina za amino, PG, ili skupina formule -A4-G, gdje
An Fc-fusion protein comprising an Fc and a human interleukin-2 (IL-2) mutein comprising a V91K substitution and an amino acid sequence at least 90% identical to the amino acid sequence set forth in SEQ ID NO:1, wherein said IL-2 mutein stimulates T regulatory cells. 
HR P20191075 T1 PATENTNI ZAHTJEV sem Fc-fuzijski protein koji sadrži Fc 1 mutein humanog interleukina-2 (IL-2) koji sadrži V9IK supstituciju 1 aminokiselinsku sekvencu najmanje 90% identičnu sa aminokiselinskom sekvencom navedenom u SEQ ID NO:1, pri čemu navedeni IL-2 mutein stimulira T regulatorne stanice.
The composition according to embodiment 8, wherein the pH adjusting substance is a carbonate. 
Pripravak prema zahtjevu 8, naznačen time da tvar za prilagođavanje pH je karbonat.
Compounds of the invention wherein R1 is NOR with R being hydrogen, (C1-6)alkyl or (C1-6)acyl and compounds of the invention wherein R3 is (C1-15)acyl are readily obtained by methods well known in the art. 
Spojeve prema ovom izumu gdje R! je NOR, gdje R je vodik, (C;.4) alkil ili (C,.6) acil, i spojeve prema ovom izumu gdje R? je (Ci.15) acil, lako se dobije postupcima dobro poznatim u struci.
Further, in the method of producing a piceatannol-containing composition according to the present invention, the aqueous alcohol-based solvent is preferably aqueous ethanol, or the aqueous ketone-based solvent is preferably aqueous acetone. 
Sastav koji sadrži piceatanol, prema zahtjevu 1 ili 2, naznačen time, da vodena otopina je vodeni etanol ili vodeni aceton.
A process according to claim 1 wherein the film-forming polymer is selected from the group consisting of acrylic acid, methacrylic acid, methoxyethylacrylate, cellulose acetate, ethylene oxide and polyethylene oxide, ethylene vinyl acetate copolymer, methyl cellulose, polyvinyl acetate, polyvinyl alcohol, polyvinyl pyrrolidone, polytetrafluorethylene and polyvinylidene chloride. 
Postupak prema zahtjevu 1, naznačen time, da je polimer koji tvori film odabran iz skupine koju čine akrilna kiselina, metakrilna kiselina, metoksietilakrilat, celulozni acetat, etilen oksid 1 polietilen oksid, kopolimer etilen vinil acetata, metil celuloza, polivinil acetat, polivinil alkohol, polivinil pirolidon, politetrafluoretilen i poliviniliden klorid.
A process according to any one of claims 1 - 2 wherein mixing is accomplished in a mixer with a horizontally placed stirrer shaft lifting the biomass. 
Postupak prema patentnom zahtjevu 1, naznačen time što je miješanje osigurano pomoću miješalice sa horizontalno postavljenom miješajućom osovinom koja podiže biomasu.
is -H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl; 
je -H, opcionalno supstituirani alkil, opcionalno supstituirani alkenil, opcionalno supstituirani alkinil, opcionalno supstituirani cikloalkil, opcionalno supstituirani cikloalkenil, opcionalno supstituirani heterociklil, opcionalno supstituirani aril, opcionalno supstituirani heteroaril, opcionalno supstituirani aralkil, ili opcionalno supstituirani heteraralkil; je C(O)Ry;
The mobile station device (50) according to claim 1 or 2, wherein the mobile station device (50) is further adapted to, in the uplink synchronous status, not perform uplink timing alignment based on the timing deviation information included in the random access response (S02). 
provodi usklađivanje vremena uzlazne veze na temelju informacije o odstupanju sinkronog vremena, u slučaju da je, kod asinkronog statusa uzlazne veze, informacija o odstupanju sinkronog vremena uključena u odgovor sa slučajnim pristupom (S02);
By increasing protein yield from recombinant manufacturing process, these systems and methods improve the efficiency and cost of manufacturing therapeutic proteins. Particularly, one embodiment includes a method of increasing the amount of a protein of interest available for recovery from a sample containing other components and following a first purification step of the sample comprising: exposing a filter through which the sample has been passed to an elution buffer wherein exposure to the elution buffer releases the protein of interest from the filter for subsequent recovery. 
PATENTNI ZAHTJEVI Metoda za povećanje količine proteina od interesa dostupnog za iskorištenje iz uzorka koji sadrži druge sastavnice 1 koja slijedi prvi korak pročišćavanja uzorka obuhvaća: izlaganje pozitivno nabijenog dubinskog filtra kroz koji je uzorak prošao soli elucijskog pufera pri čemu izlaganje elucijskom puferu oslobađa protem od interesa iz filtra za sljedeće iskorištenje, pri čemu sol elucijskog pufera ima provodljivost od najmanje 20 mS/cm.